In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patients

Session Poster Session 2

Speaker Catia Ferreira

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : C Ferreira (Coimbra,PT), AS Martinho (Coimbra,PT), JP Almeida (Coimbra,PT), AZ Freitas (Coimbra,PT), JA Ferreira (Coimbra,PT), C Domingues (Coimbra,PT), J Milner (Coimbra,PT), S Costa (Coimbra,PT), F Franco (Coimbra,PT), H Vieira (Coimbra,PT), R Coutinho (Coimbra,PT), R Baptista (Coimbra,PT), L Goncalves (Coimbra,PT)

Authors:
C Ferreira1 , AS Martinho1 , JP Almeida1 , AZ Freitas1 , JA Ferreira1 , C Domingues1 , J Milner1 , S Costa1 , F Franco1 , H Vieira1 , R Coutinho1 , R Baptista1 , L Goncalves1 , 1University Hospitals of Coimbra, Cardiology A - Coimbra - Portugal ,

Citation:

BACKGROUND AND PURPOSE:The addition of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) to standard therapy of heart failure with reduced ejection fraction (HFrEF) has proved to improve outcomes. Cardiopulmonary exercise testing (CPET)-derived ergometric variables, as peak oxygen consumption (VO2), are used to determine heart transplant (HTx) eligibility. We aimed to analyse the impact of ARNI therapy in CPET variables.

METHODS: We conducted a retrospective, observational cohort study, including 19 patients with symptomatic HFrEF with a left ventricular (LV) ejection fraction (LVEF) <35% and whose functional capacity was evaluated by CPET less than 6 months before initiating ARNI. We excluded patients who had implanted a cardiac resynchronization therapy device (CRT) or were submitted to heart surgery less than 6 months before the first CPET. A follow-up CPET was conducted 7±4 months after starting ARNI. 

RESULTS: Mean age was 55±12 years and 90% were male.Mean LVEF was 26±6% and before initiating ARNI, all patients were on optimal medical therapy, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (100%), ß-blockers (94.7%) and mineralocorticoid receptor antagonists (89.5%). Moreover, 9 patients had an implantable cardioverter defibrillator (D) and 9 patients had a CRT-D.Regarding aetiology, 11 had ischemic heart disease, 6 had dilated cardiomyopathy, 1 had corrected transposition of great arteries and 1 had LV non-compaction. The majority of the patients (73.7%) were on maximal doses of ARNI (97/103mg bid); the remaining were on intermediate dose (49/51 bid). Following ARNI, peak VO2significantly increased from 15.4±5.2 to 17.0±4.0 mL.kg-1.min-1(mean absolute increase of +1.5 mL.kg-1.min-1, p=0.03). Among the 7 patients with peak VO2<14 mL.kg-1.min-1, 3 (43%) improved peak VO2to values >14 mL.kg-1.min-1, pulling the patients out of one of the classical HTx eligibility markers. Regarding other ergometric variables, a numerically increase was observed in mean total exercise duration (12:45 to 13:27 min), in respiratory exchange ratio (RER) (1.08±0.11 to 1.12±0.08) and in peak oxygen pulse (9.9±2.7 to 10.6±2.6 mL.beat-1). Conversely, the mean respiratory efficiency index (VE/VCO2) following ARNI remained similar. 

CONCLUSION: In this cohortof HFrEF patients, ARNI significantly improved peak VO2, a major prognostic predictor. Importantly, 3 out of 7 patients with a peak VO2within the HTx threshold recovered to ineligibility values.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are